Dr. Stanley Schwartz talks about the best way to determine beta cell function and says that there are actually several indicators that might need to be used. He suggests that there may be several steps that need to be taken including genotyping patients, looking at both classic markers and newer ones, such as c-peptides, and other factors such as inflammatory markers and micro-albumin levels….
More videos in this series with Dr. Schwartz
Stanley Schwartz, MD, has been awarded the honor of being a TOP DOC by Philadelphia Magazine many times over the years, including 2009, 2010 and 2011 for the treatment of diabetes and metabolic syndrome. For over 30 years, Dr. Schwartz was an Associate Professor at the University of Pennsylvania, most recently directing the Diabetes Program at the Philadelphia Heart Institute. Dr. Stanley Schwartz is a new Affiliate of the Main Line Health System, and an Emeritus Associate Professor of Medicine at the University of Pennsylvania, currently in a private practice in Ardmore, Pa. Dr. Schwartz received his MD in 1973 from the University of Chicago in Chicago, Illinois. He then completed his residency at the University of Pennsylvania, followed by a fellowship in endocrinology and metabolism at the University of Chicago.
Dr. Schwartz serves on the following Advisory Boards: Eli Lilly, Inc.; Amylin Pharmaceuticals; Takeda; Janssen; sanofi-aventis; and Santarus
He is also part of the following speaker’s bureaus: Merck; Eli Lilly; Amylin Pharmaceuticals; Takeda; Santarus; BMS; Astra-Zeneca; and Novo Novartis.
Diabetes In Control is honored to also have Dr. Schwartz on our Advisory Board as well as a frequent contributor to our newsletters. You can find all of Dr. Schwartz’s Diabetes In Control articles here.